JAMA Network
About The Study: This cross-sectional study found a substantial increase in glucagon-like peptide-1 (GLP-1) per-patient days supplied in employer plans over the study period (2021-2024), with higher growth in plans that covered GLP-1s for weight loss. With increases in utilization, the estimate of differential per member per month cost for GLP-1 coverage is increasing over time and could signal higher financial burden on patients and payers in the future, though some of the added drug cost (yet unquantified) is likely offset by lower medical spending.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
